Trial Profile
A non interventional post authorization safety study (PASS) on the rabeprazole's administration to adults with gastro-oesophageal reflux disease (GORD).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2010
Price :
$35
*
At a glance
- Drugs Rabeprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Adverse reactions
- 27 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Apr 2010 Actual end date (Nov 2005) added as reported by ClinicalTrials.gov.
- 27 Apr 2010 Actual patient number (191) added as reported by ClinicalTrials.gov.